Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MK-1308A plus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
CTR20211819Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of quavonlimab + pembrolizumab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Nov 2021; status: completed.
02
Drugs
quavonlimab + pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211819.